Select Page ::

Healthcare Nanotechnology (Nanomedicine) Market Analysis by Size, Share, Top Key Manufacturers, Demand Overview, Regional Outlook And Growth Forecast…

Posted on April 25, 2020 by Prof Baldwin

Endo International

Global Healthcare Nanotechnology (Nanomedicine) Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=210503&utm_source=COD&utm_medium=888

Global Healthcare Nanotechnology (Nanomedicine) Market Regions and Countries Level Analysis

The regional analysis is a very complete part of this report. This segmentation highlights Healthcare Nanotechnology (Nanomedicine) sales at regional and national levels. This data provides a detailed and accurate analysis of volume by country and an analysis of market size by region of the world market.

The report provides an in-depth assessment of growth and other aspects of the market in key countries such as the United States, Canada, Mexico, Germany, France, the United Kingdom, Russia and the United States Italy, China, Japan, South Korea, India, Australia, Brazil and Saudi Arabia. The chapter on the competitive landscape of the global market report contains important information on market participants such as business overview, total sales (financial data), market potential, global presence, Healthcare Nanotechnology (Nanomedicine) sales and earnings, market share, prices, production locations and facilities, products offered and applied strategies. This study provides Healthcare Nanotechnology (Nanomedicine) sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Why choose us:

We offer state of the art critical reports with accurate information about the future of the market.

Our reports have been evaluated by some industry experts in the market, which makes them beneficial for the company to maximize their return on investment.

We provide a full graphical representation of information, strategic recommendations and analysis tool results to provide a sophisticated landscape and highlight key market players. This detailed market assessment will help the company increase its efficiency.

The dynamics of supply and demand shown in the report offer a 360-degree view of the market.

Our report helps readers decipher the current and future constraints of the Healthcare Nanotechnology (Nanomedicine) market and formulate optimal business strategies to maximize market growth.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=210503&utm_source=COD&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Healthcare Nanotechnology (Nanomedicine) market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Healthcare Nanotechnology (Nanomedicine) market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Healthcare Nanotechnology (Nanomedicine) Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Healthcare Nanotechnology (Nanomedicine) Market Size, Healthcare Nanotechnology (Nanomedicine) Market Growth, Healthcare Nanotechnology (Nanomedicine) Market Forecast, Healthcare Nanotechnology (Nanomedicine) Market Analysis

More:
Healthcare Nanotechnology (Nanomedicine) Market Analysis by Size, Share, Top Key Manufacturers, Demand Overview, Regional Outlook And Growth Forecast...

Knee injection shows promise as osteoarthritis treatment in mice – Drug Target Review

Posted on January 22, 2021 by Prof Baldwin

Scientists have found that a new knee injection using nanomedicine could prevent the effects of osteoarthritis.

A group of scientists have discovered a potential method to cure osteoarthritis. According to the researchers, a simple knee injection could stop the diseases effects. The study was conducted at the University of Pennsylvania, US.

The researchers showed that they could target a specific protein pathway in mice to halt cartilage degeneration over time. Building on that finding, they were able to show that treating mice with surgery-induced knee cartilage degeneration through the same pathway via nanomedicine could dramatically reduce the cartilage degeneration and knee pain.

Our lab is one of the few in the world studying epidermal growth factor receptor (EGFR) signalling in cartilage and from the beginning, we have found that EGFR deficiency or inactivation accelerates osteoarthritis progression in mice, said one of the researchers Associate Professor Ling Qin. Thus, we proposed that its activation could be used to treat osteoarthritis and in this study, we have proven for the first time that over-activating it inside the knee blocks the progression of osteoarthritis.

The researchers compared typical mice with those that had a ligand that bound to EGFR that was over-overexpressed in chondrocytes, the building blocks of cartilage. This overexpression drives the over-activation of EGFR signalling in knee cartilage. When examining them, the mice with overexpressed HBEGF (the EGFR ligand) were found to consistently have enlarged cartilage, meaning that it was not wearing away like the mice who had normal EGFR activity. Moreover, when these mice aged to adulthood, their cartilage was resistant to degeneration and other hallmarks of osteoarthritis, even if their knees meniscus was damaged.

To further prove that the over-activated EGFR was the reason for the mices resiliency, the researchers found that gefitinib treatments, which are designed to block EFGR function, took away the protection against cartilage degeneration.

In a new series of tests, the researchers created nanotherapeutics by attaching a potent EGFR ligand, transforming growth factor-alpha, onto synthetic nanoparticles, to inject into mice who already had cartilage damage in their knees.

Free EGFR ligands have a short half-life and cannot be retained inside of a joint capsule due to their small size, explained Associate Professor Zhiliang Cheng, the co-corresponding authors on the paper. Nanoparticles help to protect them from degradation, restrict them within the joint, reduce off-target toxicity and carry them deep inside dense cartilage to reach chondrocytes.

When mice were injected with these nanotherapeutics, the researchers saw that they slowed cartilage degeneration and bone hardening, as well as eased knee pain. There also were no major side effects seen in the mice who were treated.

While many of the technical aspects of this application still need to be worked out, the ability to stop or slow the course of osteoarthritis with an injection rather than surgery would dramatically change how we feel and function as we age and after injury, said one of the studys co- authors, Dr Jaimo Ahn.

There is a great unmet medical need for a disease-modifying osteoarthritis drug, Qin said. In the future, we will optimise the drug design and test it in large animals before proceeding to clinical trials. We hope our research could lead to a novel drug that will improve the health and well-being of the more than 27 million osteoarthritis patients in the US.

The findings were published in Science Translational Medicine.

Excerpt from:
Knee injection shows promise as osteoarthritis treatment in mice - Drug Target Review

Global Cancer Nanomedicine Market Booming Demand Leading To Exponential CAGR Growth By 2027 The Courier – The Courier

Posted on January 22, 2021 by Prof Baldwin

The Report Titled onCancer Nanomedicine Market Report- Development Trends, Market Size, Industry Opportunities and Competitive Landscape in 2021firstly introduced the Cancer Nanomedicine Industry basics:The report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors.The report takes into account theimpact of the COVID-19 pandemic on the Cancer Nanomedicine marketand is perfect for precision and accuracy that will help to meet business requirements at affordable rates. By using Cancer Nanomedicine market report, strengths and weaknesses as well as threats and opportunities for the business can be known. Defining the problem and objectives, collecting and generating market data with the supporting statistics, everything is performed in a streamlined process which makes this report highly accurate.

The information of Cancer Nanomedicine market analysis report covers major technological, scientific and economic developments in industrial, pharmaceutical and high technology organizations. This large scale report helps to achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Market Analysis and Insights: Global Cancer Nanomedicine Market:

Cancer nanomedicine market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to grow at a CAGR of 12.50% in the above-mentioned forecast period.

Get more information on Global Cancer Nanomedicine Market Research Report by requesting FREE Sample Copy at:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-nanomedicine-market&AS

The major players who are leading the Cancer Nanomedicine market throughout the globe are:

Market Segmentation

By Type (Inorganic Nanoparticles, Organic Nanoparticles)

By Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents)

Some Of The Major Highlights Of TOC Covers:-

1 INTRODUCTION

1.1 Objectives Of The Study

1.2 Cancer Nanomedicine Market Definition

2 MARKET SEGMENTATION

2.1 Cancer Nanomedicine Markets Covered

2.2 Europe Weight Management Market: Geographical Scope

3 MARKET OVERVIEW

3.1 Drivers

4 EXECUTIVE SUMMARY

4.1 Europe Weight Management Market: Segmentation

5 PREMIUM INSIGHTS

5.1 Increasing Government Initiatives Towards Management And Growing Consumption Of Healthy Diets Are Expected To Drive The Cancer Nanomedicine Market In The Forecast Period Of 2020 To 2027

Continued.

Browse Global Cancer Nanomedicine Market Research Report with detailed TOC: https://www.databridgemarketresearch.com/toc/?dbmr=global-cancer-nanomedicine-market&AS

Global Cancer Nanomedicine Market Scope and Market Size

Cancer nanomedicine market is segmented on the basis of type, agent type, mechanism, cancer type, imaging technique, and phase. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Regional Analysis

This section covers regional segmentation which accentuates on current and future demand for Cancer Nanomedicine market across This section covers regional segmentation which accentuates on current and future demand for COVID-19 Cancer Nanomedicine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions. Further, the report focuses on demand for individual application segment across all the prominent regions.

Get detailed COVID-19 impact analysis on the Cancer Nanomedicine Market:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-nanomedicine-market&AS

Key Pointers Covered In The Cancer Nanomedicine Market Industry Trends And Forecast To 2027

The study provides an in-depth analysis, current trends, and future estimations of theglobal Cancer Nanomedicine marketto elucidate the imminent investment pockets.

Comprehensive analysis of factors that drive and restrict the Cancer Nanomedicine market growth is provided.

The Cancer Nanomedicine Industry report provides a qualitative and quantitative analysis of the current External Storage market trends, forecasts, and market size from 2020 to 2027 to determine new opportunities.

Porters Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry.

Extensive analyses of key segments of the industry help understand the types of products and technologies used across various geographical regions.

About Data Bridge Market Research Private Ltd:

Data Bridge Market Research PvtLtdis a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.

Contact:

Data Bridge Market Research

US:+1 888 387 2818

UK:+44 208 089 1725

Hong Kong:+852 8192 7475

Email:-Corporatesales@databridgemarketresearch.com

See the rest here:
Global Cancer Nanomedicine Market Booming Demand Leading To Exponential CAGR Growth By 2027 The Courier - The Courier

Clene Nanomedicine Aims to be the Gold Standard in Neurodegenerative Disease – BioBuzz

Posted on January 22, 2021 by Prof Baldwin

Clene Nanomedicine, one of Marylands Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the Nasdaq Exchange and $31.9 million that will be used to advance the companys gold nanocrystal-based treatment for neurodegenerative diseases.

Clene is developing a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals, which are used to amplify bioenergetic reactions in patients in order to drive intracellular biological reactions. Chief Executive Officer Rob Etherington said bioenergetic nanotherapeutics are a clean break from pharmaceutical drug development that uses classical synthetic chemistry.

Using gold as a therapeutic is not a new concept. Gold-salt injections were historically used to treat rheumatoid arthritis decades ago, but were dropped due to health concerns and toxicity issues.

Funds from the merger with Tottenham, a special purpose acquisition company (SPAC), will be used to advance Clenes lead asset, CNM-Au8, a bioenergetic nanocatalyst under development as an add-on treatment for neurodegenerative diseases like Parkinsons disease, multiple sclerosis and Amyotrophic Lateral Sclerosis (ALS). CNM-Au8 is designed to catalyze biocelluar reactions and so far the company has seen the asset live up to its promise in clinical studies.

Although Clenes corporate offices are in Utah, the bulk of the companys research is conducted in Cecil County, Maryland. Approximately three-fourths of the companys employees are located in Maryland, Etherington said. The company conducts all R&D and manufacturing in Maryland, as well as its commercialization activities.

Maryland has been a perfect anchor for Clene, Etherington said.

While the company raised a significant amount of funds through the merger, Etherington said Maryland was one of the companys earliest financial backers through a loan arrangement. He said predicted his company and the state will continue to have a strong relationship in the years ahead.

The state has been a true supporter. It was also gratifying to be recognized as a Future 2020 company because we have built a home in Maryland, he said.

Etherington predicted the next 18 months will be important for the company due to a planned readout of the companys asset. The funds raised in the merger will be used to carry CNM-Au8 into Phase II and Phase III studies that aim to address neurodegenerative diseases of high unmet medical need, such as multiple sclerosis, Parkinsons disease and amyotrophic lateral sclerosis (ALS). CNM-Au8 is currently being assessed in a Phase II study for the treatment of chronic optic neuropathy in patients with multiple sclerosis and is in Phase II and Phase III studies for disease progression in patients with ALS. Both Phase II studies are expected to read out this year. Its also being studied in a Phase II Parkinsons disease trial. The company reported interim data from the study last year and additional data is expected in the first half of 2021. Clene also plans to launch an additional Phase IIb Parkinsons disease efficacy study with CN<-Au8 by the end of the year.

While CNM-Au8 is showing promise, its not designed to replace any medication currently being used by a patient for one of these diseases. Rather, its designed to work alongside those medications. Clenes compound is designed to enhance the intracellular biological actions necessary to repair and reverse neuronal damage, Etherington said.

Clenes gold nanocrystals are grown in treated water and patients drink the product when it is ready. By combining the nanocrystal therapy with ongoing treatments for these neurodegenerative diseases, Etherington said the goal is to reverse neurodegeneration.

We want to let the cell take care of its own housekeeping and enhance whats naturally occurring in the central nervous system, he said.

In addition to the gold nanocrystal compound, Clene is developing a silver and zinc asset for COVID-19. CNM-AgZn17 is Clenes second key asset intended for broad anti-viral and anti-microbial use. A Phase II study is planned in Brazil to treat acutely symptomatic non-hospitalized patients with COVID-19.

Alex Keown is a freelance journalist who writes about a variety of subjects including the pharma, biotech, and life science industries. Prior to freelancing, Alex has served as a staff writer and editor for several publications.

See original here:
Clene Nanomedicine Aims to be the Gold Standard in Neurodegenerative Disease - BioBuzz

Pham named Guy and Ella Mae Magness Professor of Medicine – Washington University School of Medicine in St. Louis

Posted on February 14, 2021 by Prof Baldwin

Visit the News Hub

Rheumatologist develops nanomedicine approaches for inflammatory diseases

Christine Pham, MD, works in her lab in 2017. A rheumatologist who specializes in nanomedicine approaches to inflammatory diseases, Pham has been named the inaugural Guy and Ella Mae Magness Professor of Medicine at Washington University School of Medicine in St. Louis.

Christine Pham, MD, director of the Division of Rheumatology at Washington University School of Medicine in St. Louis, has been named the inaugural Guy and Ella Mae Magness Professor of Medicine.

Pham was chosen for the honor in recognition of her work involving nanomedicine approaches in the treatment of inflammatory diseases and the role of biomolecules known as proteases in inflammatory processes. The Department of Medicine established the Guy and Ella Mae Magness Professorship in Medicine in 2018 with proceeds from the Ella Mae Magness Trust.

I am delighted to recognize Dr. Phams accomplishments with this professorship named for two noted health professionals and graduates of Washington University, said Chancellor Andrew D. Martin. Dr. Guy and Ella Mae Magness worked tirelessly to promote public health, and their dedication to medicine and to our community is reflected in Dr. Pham. She has distinguished herself both in her research on the role of neutrophil proteases in inflammatory arthritis and her commitment to mentoring and supporting junior faculty.

Pham will be officially installed when the COVID-19 pandemic is under control. She will be installed by David H. Perlmutter, MD, executive vice chancellor for medical affairs, the George and Carol Bauer Dean of the School of Medicine, and the Spencer T. and Ann W. Olin Distinguished Professor; and Victoria J. Fraser, MD, the Adolphus Busch Professor of Medicine and head of the Department of Medicine.

Also a professor of pathology & immunology, Pham more recently has focused on nanomedicine approaches for various inflammatory conditions including rheumatoid arthritis, a chronic, incapacitating disease involving painful, swollen joints. Nanomedicine involves using tiny transport particles for a concentrated delivery of therapeutics directly to specific sites such as the joints. Nanoparticle formulations also help protect unstable drugs from degradation in the bloodstream, thereby unlocking the potential of new kinds of therapeutics. Pham employs a nanocomplex that protects an unstable experimental arthritis drug and efficiently delivers it to the joints, where it suppresses specific and harmful pathways that cause inflammation in diseased tissues without affecting the global immune system.

Christine Pham exemplifies faculty who are the foundation of what we do at the School of Medicine today and are poised to do tomorrow, Perlmutter said. She is an outstanding physician-scientist with expertise in immunology, rheumatology and translational approaches to inflammatory arthritis and autoimmune diseases. She draws upon this broad expertise to promote multidisciplinary research in inflammatory diseases with the goal of developing better treatments for patients.

Pham directs Washington Universitys Rheumatic Diseases Research Resource-Based Center, which provides resources to accelerate basic and translational research into rheumatic diseases, aiming to improve treatment for people suffering from rheumatic diseases such as arthritis, lupus and vasculitis, an inflammation of the blood vessels.

Before moving into nanomedicine, Pham explored the role of proteases enzymes that break down proteins produced by certain white blood cells in inflammatory diseases. Her laboratory cloned and characterized the protease cathepsin C. Her work led to the development of cathepsin C inhibitors that are in clinical trials for a form of chronic inflammatory lung disease.

Dr. Christine Phams work on the role of innate and adaptive immune responses in various inflammatory processes has led to the identification of new therapeutic targets for these diseases, Fraser said. She is an esteemed member of the Washington University community who has a deep commitment to innovative multidisciplinary research. She is an outstanding mentor and champion for residents, fellows and junior faculty. She is well-deserving of this recognition.

Guy N. Magness, MD, (1899-1982) earned his medical degree at the School of Medicine in 1928. He began his career as a school physician and in 1931 rose to become director of medical services for University City Public Schools, where he served for 40 years. He also held the position of director of health for University City from 1952 to 1981, gaining recognition as a leader in the field of health problems in public education. In 1963, he co-chaired a polio vaccination drive, and more than a million St. Louisans were immunized as a result. He was in the Army Medical Corps in World War II and retired from the Army reserve as a colonel.

Ella Mae Magness (1905-2000) was Missouris director of public health from the late 1930s to the early 1940s. In the late 1940s, she was the western regional director of public health covering seven states. She earned a certificate in nursing in 1928 and a bachelors degree in nursing in 1937, both from Washington University School of Nursing. She earned a masters degree in public health from Columbia University in New York, and she served in the U.S. Armys Nurse Corps during World War II, attaining the rank of lieutenant colonel.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Continued here:
Pham named Guy and Ella Mae Magness Professor of Medicine - Washington University School of Medicine in St. Louis

Continuous Venovenous Hemofiltration (CVVH) Product Market: Innovative trends with next largest revenue-generating business opportunity by 2027 – The…

Posted on November 19, 2020 by Prof Baldwin

TheGlobal Continuous Venovenous Hemofiltration (CVVH) Product Markethas witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2020-2027). The research presents a complete assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical data, and statistically supported and industry-validated market data.

Continuous Venovenous Hemofiltration (CVVH) Product Market report presents a detailed analysis of the parent market based on elite players, present, past and futuristic data which will serve as a profitable guide for all the industry competitors. Top players in the industry includeGE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany), Guerbet (France), Lantheus (US), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India), Spago Nanomedicine (Sweden), Taejoon Pharm (South Korea), Jodas (India), Magnus Health (India).

Click to get a FREE Sample PDF Copy Here:https://www.stratagemmarketinsights.com/sample/584

The Continuous Venovenous Hemofiltration (CVVH) Product Market report begins with a basic overview of the industry lifecycle, definitions, classifications, applications, and industry chain structure, and all these together will help leading players understand the scope of the market. The study also coversmarket status, share, future patterns, development rate, deals, SWOT analysis, channels, merchants, and improvement gets ready for the anticipated year between 2020-2027.

The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. The rapidly changing industry scenario and initial and future assessment of the impact are covered in the report. The Continuous Venovenous Hemofiltration (CVVH) Product market report puts together a concise analysis of the growth factors influencing the current business scenario across various regions. Significant information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present an ensemble prediction.

It aims to strategically analyze the market with respect to individual growth trends, prospects, and their contribution to the market. The report attempts to forecast the market size for 5 major regions, namely,North America, Europe, Asia Pacific (APAC), Middle East, and Africa (MEA), and Latin America.This report helps to identify the key growth countries and regions.

What Continuous Venovenous Hemofiltration (CVVH) Product Market report offers?

1. Continuous Venovenous Hemofiltration (CVVH) Product Market share assessments for the regional and country-level segments2. Market share analysis of the top industry players3. Continuous Venovenous Hemofiltration (CVVH) Product Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)4. Strategic recommendations in key business segments based on the market estimations5. Competitive landscape covering the following points:Company Overview, Product Portfolio, Financial Performance, Recent Highlights, Strategies

In the end, the Continuous Venovenous Hemofiltration (CVVH) Product report offers a short outline of the dealers, distributors, suppliers. Along with the Continuous Venovenous Hemofiltration (CVVH) Productsales channel, analysis findings, conclusions, and results. Finally, provide info regarding new entrants within the Continuous Venovenous Hemofiltration (CVVH) Product market. The study suggests a brand new proposition to spice up Continuous Venovenous Hemofiltration (CVVH) Product market price and nurture businesses. Correspondingly explains the current global Continuous Venovenous Hemofiltration (CVVH) Product market and the coming development of the business.

Any customization with this report, please get in touch with SMI experts athttps://www.stratagemmarketinsights.com/quiry/584

Name: Mr. ShahPhone: US +12067016702 / UK +4402081334027Email: [emailprotected]

Visit Our Blog:Shubham

Go here to see the original:
Continuous Venovenous Hemofiltration (CVVH) Product Market: Innovative trends with next largest revenue-generating business opportunity by 2027 - The...

Targeted nanomedicines for the treatment of bone disease and regeneration – DocWire News

Posted on December 23, 2020 by Prof Baldwin

This article was originally published here

Med Res Rev. 2020 Dec 21. doi: 10.1002/med.21759. Online ahead of print.

ABSTRACT

Targeted delivery by either passive or active targeting of therapeutics to the bone is an attractive treatment for various bone related diseases such as osteoporosis, osteosarcoma, multiple myeloma, and metastatic bone tumors. Engineering novel drug delivery carriers can increase therapeutic efficacy and minimize the risk of side effects. Developmnet of nanocarrier delivery systems is an interesting field of ongoing studies with opportunities to provide more effective therapies. In addition, preclinical nanomedicine research can open new opportunities for preclinical bone-targeted drug delivery; nevertheless, further research is needed to progress these therapies towards clinical applications. In the present review, the latest advancements in targeting moieties and nanocarrier drug delivery systems for the treatment of bone diseases are summarized. We also review the regeneration capability and effective delivery of nanomedicines for orthopedic applications.

PMID:33347711 | DOI:10.1002/med.21759

View original post here:
Targeted nanomedicines for the treatment of bone disease and regeneration - DocWire News

Healthcare Nanotechnology (Nanomedicine) Market Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts to…

Posted on January 8, 2021 by Prof Baldwin

The Healthcare Nanotechnology (Nanomedicine) Market was valued at US$ XX million in 2019 and is projected to reach US$ XX million by 2025, at a CAGR of XX% during the forecast period. In this study, 2019 has been considered as the base and 2020 to 2025 as the forecast period to estimate the market size for Healthcare Nanotechnology (Nanomedicine) Market

Deep analysis about Healthcare Nanotechnology (Nanomedicine) market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Healthcare Nanotechnology (Nanomedicine) Market.

Get a Sample Copy of the Global Healthcare Nanotechnology (Nanomedicine) Market Report at: https://i2iresearch.com/report/healthcare-nanotechnology-(nanomedicine)-market-report-global-regional-industry-forecast-2019-2024/#download-sample

The Healthcare Nanotechnology (Nanomedicine) Market can be split based on product types, major applications and regions.

By Disease:Cardiovascular DiseasesOncological DiseasesNeurological DiseasesOrthopedic DiseasesInfectious DiseasesOther Diseases

Key Applications:1. Drug Delivery2. Biomaterials3. Active Implants4. Diagnostic Imaging5. Tissue Regeneration6. Other

Healthcare Nanotechnology (Nanomedicine) Market Key companies covered / Analyzed in the report are:

Sanofi SACelegene CorporationCytImmune Sciences Inc.Johnson & JohnsonLuminex CorporationMerck & Co. Inc.NanobiotixPfizer Inc.Starpharma Holdings LimitedTaiwan Liposome Company Ltd

The Healthcare Nanotechnology (Nanomedicine) Market report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/healthcare-nanotechnology-(nanomedicine)-market-report-global-regional-industry-forecast-2019-2024/

Key questions Answered in the report:1. What is the current size of the Healthcare Nanotechnology (Nanomedicine) Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Healthcare Nanotechnology (Nanomedicine) Market?4. What is the likely market forecast & how will be impacted Healthcare Nanotechnology (Nanomedicine) Market?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Healthcare Nanotechnology (Nanomedicine) Market?

The report also analysis the impact of COVID 19 based on a scenario based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

https://neighborwebsj.com/

See the rest here:
Healthcare Nanotechnology (Nanomedicine) Market Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts to...

Nanomedicine Market 2019 Global Outlook, Research, Trends and Forecast to 2025 – The Haitian-Caribbean News Network

Posted on December 4, 2020 by Prof Baldwin

Nanomedicine Market Forecast 2020-2026

The Global Nanomedicine Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Nanomedicine Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://www.upmarketresearch.com/home/requested_sample/11972

The Report Covers the Following Companies:CombimatrixAblynxAbraxis BioscienceCelgeneMallinckrodtArrowhead ResearchGE HealthcareMerckPfizerNanosphereEpeius BiotechnologiesCytimmune SciencesNanospectra Biosciences

By Types:Quantum dotsNanoparticlesNanoshellsNanotubesNanodevices

By Applications:Segmentation encompasses oncologyInfectious diseasesCardiologyOrthopedicsOthers

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://www.upmarketresearch.com/home/request_for_discount/11972

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Important Facts about Nanomedicine Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://www.upmarketresearch.com/home/enquiry_before_buying/11972

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Organization UpMarketResearchAddress 500 East E Street, Ontario, CA 91764, United States.

The rest is here:
Nanomedicine Market 2019 Global Outlook, Research, Trends and Forecast to 2025 - The Haitian-Caribbean News Network

NANOBIOTIX Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris – Business Wire

Posted on December 13, 2020 by Prof Baldwin

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Euronext: NANO ISIN : FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that trading of its ordinary shares on the regulated market of Euronext in Paris (Euronext Paris) will be temporarily halted, at the Companys request, from the opening of the market at 9:00 AM CET. This trading halt takes place in the context of the initial public offering of the Company on the Nasdaq Global Select Market, in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Companys American Depositary Shares (ADSs) on the Nasdaq Global Select Market.

This suspension will be effective until a new communication is released by the Company. Trading on the regulated market of Euronext Paris is expected to resume today, December 11, 2020, at approximately 4:00 pm (CET), which is the earliest time ADSs are expected to begin trading on the Nasdaq Global Select Market (10:00 am (EST)) under the ticker symbol NBTX.

About NANOBIOTIX

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). Its headquarters are in Paris, France. Nanobiotix has a subsidiary, Curadigm, located in France and the United States, as well as a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the AMF under number R.20-010 on May 12, 2020 and in its amendment filed with the AMF under number D.20-0339-A01 on November 20, 2020 (copies of which are available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs of Nanobiotix in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

A French listing prospectus comprising (i) the 2019 universal registration document filed with the AMF under number R.20-010 on May 12, 2020, as completed by a first amendment to such universal registration document filed with the AMF under number D.0339-A01 on November 20, 2020 and a second amendment to such universal registration document, which will be filed with the AMF on December 11, 2020, and (ii) a Securities Note (Note dopration), including a summary of the prospectus, will be submitted to the approval by the AMF and will be published on the AMFs website at http://www.amf-france.org. Following the filing of the second amendment to the universal registration document with the AMF, copies of Companys 2019 universal registration document, as amended, will be available free of charge at the Companys head office located at 60 rue de Wattignies, 75012 Paris.

European Economic Area

In relation to each Member State of the European Economic Area (each, a Member State) no offer to the public of ordinary shares and ADSs may be made in that Member State other than:

- to any legal entity which is a qualified investor as defined in the Prospectus Regulation;

- to fewer than 150 natural or legal persons (other than a qualified investor as defined in the Prospectus Regulation); or

- in any other circumstances falling within Article 1(4) of the Prospectus Regulation,

provided that no such offer of ordinary shares and ADSs shall require us or any Underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the Underwriters and the Company that it is a qualified investor as defined in the Prospectus Regulation.

For the purposes of this provision, the expression an offer to the public in relation to any ordinary shares and ADSs in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ordinary shares and ADSs to be offered so as to enable an investor to decide to purchase any ordinary shares and ADSs, and the expression Prospectus Regulation means Regulation (EU) 2017/1129 (as amended).

France

The ADSs and the ordinary shares have not been and will not be offered or sold to the public in the Republic of France, and no offering of this prospectus or any marketing materials relating to the ADSs and the ordinary shares may be made available or distributed in any way that would constitute, directly or indirectly, an offer to the public in the Republic of France (except for public offerings defined in Article L.411-2 1 of the French Code montaire et financier).

The ordinary shares in the form of ADSs may only be offered or sold in France pursuant to article L. 411-2 1 of the French Code montaire et financier to qualified investors (as such term is defined in Article 2(e) of Regulation (EU) n 2017/1129 dated 14 June 2017, as amended) acting for their own account, and in accordance with articles L. 411-1, L. 411-2 and D. 411-2 to D.411-4, D.744-1 and D. 754-1 and D. 764-1 of the French Code montaire et financier.

This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.

Endocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy | IJN – Dove Medical Press

Posted on November 27, 2020 by Prof Baldwin

Xiaowei Wang, Yuhan Qiu, Mengyan Wang, Conghui Zhang, Tianshu Zhang, Huimin Zhou, Wenxia Zhao, Wuli Zhao, Guimin Xia, Rongguang Shao

Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, Peoples Republic of China

Correspondence: Wuli ZhaoInstitute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 10050, Peoples Republic of ChinaTel +86-10-83166673Email zwl21146@imb.pumc.edu.cnGuimin XiaInstitute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 10050, Peoples Republic of ChinaTel +86-10-63150697Email xiaguimin@126.com

Abstract: Nanomedicines (NMs) have played an increasing role in cancer therapy as carriers to efficiently deliver therapeutics into tumor cells. For this application, the uptake of NMs by tumor cells is usually a prerequisite to deliver the cargo to intracellular locations, which mainly relies on endocytosis. NMs can enter cells through a variety of endocytosis pathways. Different endocytosis pathways exhibit different intracellular trafficking routes and diverse subcellular localizations. Therefore, a comprehensive understanding of endocytosis mechanisms is necessary for increasing cellular entry efficiency and to trace the fate of NMs after internalization. This review focuses on endocytosis pathways of NMs in tumor cells, mainly including clathrin- and caveolae-mediated endocytosis pathways, involving effector molecules, expression difference of those molecules between normal and tumor cells, as well as the intracellular trafficking route of corresponding endocytosis vesicles. Then, the latest strategies for NMs to actively employ endocytosis are described, including improving tumor cellular uptake of NMs by receptor-mediated endocytosis, transporter-mediated endocytosis and enabling drug activity by changing intracellular routes. Finally, active targeting strategies towards intracellular organelles are also mentioned. This review will be helpful not only in explicating endocytosis and the trafficking process of NMs and elucidating anti-tumor mechanisms inside the cell but also in rendering new ideas for the design of highly efcacious and cancer-targeted NMs.

Keywords: nanomedicine, endocytosis pathway, clathrin, caveolae, endosome, organelle targeting

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Visit link:
Endocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy | IJN - Dove Medical Press

Iran ranks third for top researchers in Islamic world 2020 – Tehran Times

Posted on November 27, 2020 by Prof Baldwin

TEHRAN Iran ranked third for the highly cited researchers in the world among Islamic countries in 2020, according to the recently published report of Highly Cited Researchers by Web of Science.

Among the world's top researchers, 13 Islamic countries are listed, which hold a share of 3 percent (2.85%) among the world's top researchers.

Saudi Arabia with 120 researchers, Malaysia with 17, Iran with 12, and Turkey with 11 researchers have the highest number of highly cited researchers among Islamic countries.

To be included in the list of top researchers, all scientific activities over the last 10 years are evaluated at the international level, including the number of articles, number of citations, number of highly cited articles, number of citations to highly cited articles, as well as issues such as observing ethical principles in research.

So, approximately 6,389 researchers have been selected as highly cited researchers in 2020.

From Iran in 2020, similar to 2019, 12 top researchers have been included in the list of 6,389 top-cited researchers in the world.

The country's top researchers have been in the cross-field (6 people), agricultural sciences (2 people), mathematics (2 people), and engineering (2 people), respectively.

The United States is home to the highest number of Highly Cited Researchers, with 2,650 authors, representing 41.5 percent of the researchers on the list. China, home to 770 researchers is the second country has the highest concentration of Highly Cited Researchers in the world. The United Kingdom is also a hotbed of talent, with 514 authors, and Germany, Australia, Canada, the Netherlands, and France are all home to over 150 researchers each.

Research: A new website for the essence of COINS – Tdnews

Posted on November 29, 2020 by Prof Baldwin

Photo:COINS aims to realize in-body hospitals , which integrates all medical functions within the body.Smart nanomachines of a virus size will autonomously patrol the microenvironments in the body and provide diagnosticview more

Credit Image: 2020 Innovation Center of NanoMedicine

Summary

Main body

As the Kawasaki hub (COINS) of the Center of Innovation (COI) Program of the Ministry of Education, Culture, Sports, Science and Technology, the KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION Innovation Center of NanoMedicine (Director General: Kazunori Kataoka, Location; Tonomachi Kawasaki City, Abbreviation: iCONM) aiming to establish in-body hospitals by 2045 has opened a new website for Project COINS.

The contents were exhibited at Innovation JAPAN2020, that was an online matching event between Academia and Industry, organized by JST (Japan Science and Technology Agency).https://ij2020online.jst.go.jp/

COINS will continue to work for creating the innovation towards the most innovative hub in the world. We have posted what COINS thinks of 2045 and the roadmap in easy-to-understand manner. Please visit our website.https://coins.kawasaki-net.ne.jp/en/about/

Information on new website URL

In English??https://coins.kawasaki-net.ne.jp/en/about/

In Japanese ?https://coins.kawasaki-net.ne.jp/about/

The official website remains https://coins.kawasaki-net.ne.jp/en/

###

Public Interest Incorporated Foundation KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION

KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION was established in 1988 funded 100% from Kawasaki City for the purpose of coping with the hollowing out of industry and changes in the demand structure. In order to realize a higher level of market development, transforming R&D type companies, training technological capabilities to support it, human resources development, understanding market needs, etc., by utilizing the functions of the Kawasaki, KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION has been contributing to revitalize the local economy by promoting exchanges of local industry information, advancing technology and corporate exchanges with establishment of a R&D institutions, developing creative human resources through workshops and promoting businesses such as expanding sales channels through exhibition business.http://www.kawasaki-net.ne.jp/

Innovation Center of NanoMedicine (iCONM)

Innovation Center of NanoMedicine (iCONM) started its operation in April 2015 as a core research center in life science field at King SkyFront on the request of Kawasaki city that KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION utilized national policies as a business operator and proposer.It is a unique research center that the world has ever seen which is designed for the purpose of promoting open innovation through industry-academia-government/medical-engineering collaboration, prepared with state-of-the-art facilities and experimental equipment, that enables comprehensive research and development from organic synthesis / microfabrication to preclinical testing. https://iconm.kawasaki-net.ne.jp/en/

Center of Innovation Program (COI)

The COI program is a research and development program under the Ministry of Education, Culture, Sports, Science and Technology and the Japan Science and Technology Agency. The program employs the backcasting approach and set interdisciplinary and collaborative R&D themes that should be challenged at the present from the issues that are underlying in the future society. Eighteen centers have been established nationwide to realize radical innovation through industry-academia collaboration which cannot be accomplished by industry and academia alone.The Kawasaki center is the only COI center managed by local governments, not universities, and the research projects carried out there are called COINS (Center of Open Innovation Network for Smart Health).

COI: https://www.jst.go.jp/tt/EN/platform/coi.html

COINS: https://coins.kawasaki-net.ne.jp/en/

November 25, 2020

Inquiries

KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION

Innovation Center of NanoMedicine (iCONM)

COINS Research Promotion Office / Person in charge: Mami Satake

Email: [emailprotected]

Read the original post:
Research: A new website for the essence of COINS - Tdnews

SHAREHOLDER ALERT: WeissLaw LLP Reminds HCAC, TOTA, and LFAC Shareholders About Its Ongoing Investigations – PRNewswire

Posted on October 31, 2020 by Prof Baldwin

NEW YORK, Oct. 30, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY 10036(212)682-3025(888) 593-4771[emailprotected]

Hennessy Capital Acquisition Corp. IV (NASDAQ: HCAC)WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Hennessy Capital Acquisition Corp. IV(NASDAQ: HCAC)in connection with the company's merger with privately-held Canoo Holdings Ltd. ("Canoo"). Under the terms of the proposed transaction, the company will acquire Canoo through a reverse merger that will result in Canoo becoming a publicly-traded company. The deal has a pro forma equity value of approximately $2.4 billion.If you own HCAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/hennessy-capital-acquisition-corp-iv/

Tottenham Acquisition I Limited (NASDAQ: TOTA)WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tottenham Acquisition I Limited (NASDAQ: TOTA)in connection with the company's proposed merger with Clene Nanomedicine, Inc. ("Clene"). Under the terms of the agreement, Tottenham will acquire Clene through a reverse merger that will result in Clene becoming a publicly-traded company. Additionally,Clene shareholders will be entitled to receive earn-out consideration of up to an additional 8.33 million shares of the newly combined company's common stock, subject to the new company achieving certain milestones. The proposed transaction values Clene at $542.5 million. If you own TOTA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/tottenham-acquisition-i-limited/

LF Capital Acquisition Corp. (NASDAQ: LFAC)WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of LF Capital Acquisition Corp. (NASDAQ: LFAC)in connection with the proposed acquisition of Landsea Homes Incorporated ("Landsea Homes"). Under the terms of the acquisition agreement, LFAC will acquire Landsea Homes through a reverse merger that will result in Landsea Homes becoming a publicly-traded company. The combined company is expected to have a pro forma equity value of approximately $510 million. Upon closing, Landsea Homes' founder, Landsea Green Properties Co., Ltd., will own 67.4% of the newly-combined company. If you own LFAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/news/lf-capital-acquisition-corp/

SOURCE WeissLaw LLP

http://weisslawllp.com

Here is the original post:
SHAREHOLDER ALERT: WeissLaw LLP Reminds HCAC, TOTA, and LFAC Shareholders About Its Ongoing Investigations - PRNewswire

Healthcare Nanotechnology Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2026| Amgen, Teva Pharmaceuticals, Abbott – The…

Posted on November 27, 2020 by Prof Baldwin

The global Healthcare Nanotechnology market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Healthcare Nanotechnology market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global Healthcare Nanotechnology market. The authors of the report profile leading companies of the global Healthcare Nanotechnology market, such as Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith & Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International They provide details about important activities of leading players in the competitive landscape.

The report predicts the size of the global Healthcare Nanotechnology market in terms of value and volume for the forecast period 2019-2026. As per the analysis provided in the report, the global Healthcare Nanotechnology market is expected to rise at a CAGR of XX % between 2019 and 2026 to reach a valuation of US$ XX million/billion by the end of 2026. In 2018, the global Healthcare Nanotechnology market attained a valuation of US$_ million/billion. The market researchers deeply analyze the global Healthcare Nanotechnology industry landscape and the future prospects it is anticipated to create.

This publication includes key segmentations of the global Healthcare Nanotechnology market on the basis of product, application, and geography (country/region). Each segment included in the report is studied in relation to different factors such as consumption, market share, value, growth rate, and production.

Get Sample Copy of This Report:https://www.qyresearch.com/sample-form/form/1640840/global-healthcare-nanotechnology-market

The comparative results provided in the report allow readers to understand the difference between players and how they are competing against each other. The research study gives a detailed view of current and future trends and opportunities of the global Healthcare Nanotechnology market. Market dynamics such as drivers and restraints are explained in the most detailed and easiest manner possible with the use of tables and graphs. Interested parties are expected to find important recommendations to improve their business in the global Healthcare Nanotechnology market.

Readers can understand the overall profitability margin and sales volume of various products studied in the report. The report also provides the forecasted as well as historical annual growth rate and market share of the products offered in the global Healthcare Nanotechnology market. The study on end-use application of products helps to understand the market growth of the products in terms of sales.

Global Healthcare Nanotechnology Market by Product: Nanomedicine, Nano Medical Devices, Nano Diagnosis, Others, Nanomedicine has the highest percentage of revenue by type, with more than 86% in 2019.

Global Healthcare Nanotechnology Market by Application: , Anticancer, CNS Product, Anti-infective, Others, According to the application, anticancer and CNS products accounted for 17.56% and 22.70% of the market in 2019 respectively.

The report also focuses on the geographical analysis of the global Healthcare Nanotechnology market, where important regions and countries are studied in great detail.

Global Healthcare Nanotechnology Market by Geography:

Methodology

Our analysts have created the report with the use of advanced primary and secondary research methodologies.

As part of primary research, they have conducted interviews with important industry leaders and focused on market understanding and competitive analysis by reviewing relevant documents, press releases, annual reports, and key products.

For secondary research, they have taken into account the statistical data from agencies, trade associations, and government websites, internet sources, technical writings, and recent trade information.

Enquire For Customization in the Report:https://www.qyresearch.com/customize-request/form/1640840/global-healthcare-nanotechnology-market

Key questions answered in the report:

Get Full Report in your Inbox within 24 Hours at USD(3350): https://www.qyresearch.com/settlement/pre/080c593066ddd2a3acbcfafbaa986830,0,1,global-healthcare-nanotechnology-market

Table Of Contents:

1 Market Overview of Healthcare Nanotechnology1.1 Healthcare Nanotechnology Market Overview1.1.1 Healthcare Nanotechnology Product Scope1.1.2 Market Status and Outlook1.2 Global Healthcare Nanotechnology Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Healthcare Nanotechnology Market Size by Region (2015-2026)1.4 Global Healthcare Nanotechnology Historic Market Size by Region (2015-2020)1.5 Global Healthcare Nanotechnology Market Size Forecast by Region (2021-2026)1.6 Key Regions, Healthcare Nanotechnology Market Size YoY Growth (2015-2026)1.6.1 North America Healthcare Nanotechnology Market Size YoY Growth (2015-2026)1.6.2 Europe Healthcare Nanotechnology Market Size YoY Growth (2015-2026)1.6.3 Asia-Pacific Healthcare Nanotechnology Market Size YoY Growth (2015-2026)1.6.4 Latin America Healthcare Nanotechnology Market Size YoY Growth (2015-2026)1.6.5 Middle East & Africa Healthcare Nanotechnology Market Size YoY Growth (2015-2026) 2 Healthcare Nanotechnology Market Overview by Type2.1 Global Healthcare Nanotechnology Market Size by Type: 2015 VS 2020 VS 20262.2 Global Healthcare Nanotechnology Historic Market Size by Type (2015-2020)2.3 Global Healthcare Nanotechnology Forecasted Market Size by Type (2021-2026)2.4 Nanomedicine2.5 Nano Medical Devices2.6 Nano Diagnosis2.7 Others 3 Healthcare Nanotechnology Market Overview by Application3.1 Global Healthcare Nanotechnology Market Size by Application: 2015 VS 2020 VS 20263.2 Global Healthcare Nanotechnology Historic Market Size by Application (2015-2020)3.3 Global Healthcare Nanotechnology Forecasted Market Size by Application (2021-2026)3.4 Anticancer3.5 CNS Product3.6 Anti-infective3.7 Others 4 Global Healthcare Nanotechnology Competition Analysis by Players4.1 Global Healthcare Nanotechnology Market Size by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Healthcare Nanotechnology as of 2019)4.3 Date of Key Manufacturers Enter into Healthcare Nanotechnology Market4.4 Global Top Players Healthcare Nanotechnology Headquarters and Area Served4.5 Key Players Healthcare Nanotechnology Product Solution and Service4.6 Competitive Status4.6.1 Healthcare Nanotechnology Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Amgen5.1.1 Amgen Profile5.1.2 Amgen Main Business5.1.3 Amgen Healthcare Nanotechnology Products, Services and Solutions5.1.4 Amgen Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.1.5 Amgen Recent Developments5.2 Teva Pharmaceuticals5.2.1 Teva Pharmaceuticals Profile5.2.2 Teva Pharmaceuticals Main Business5.2.3 Teva Pharmaceuticals Healthcare Nanotechnology Products, Services and Solutions5.2.4 Teva Pharmaceuticals Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.2.5 Teva Pharmaceuticals Recent Developments5.3 Abbott5.5.1 Abbott Profile5.3.2 Abbott Main Business5.3.3 Abbott Healthcare Nanotechnology Products, Services and Solutions5.3.4 Abbott Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.3.5 UCB Recent Developments5.4 UCB5.4.1 UCB Profile5.4.2 UCB Main Business5.4.3 UCB Healthcare Nanotechnology Products, Services and Solutions5.4.4 UCB Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.4.5 UCB Recent Developments5.5 Roche5.5.1 Roche Profile5.5.2 Roche Main Business5.5.3 Roche Healthcare Nanotechnology Products, Services and Solutions5.5.4 Roche Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.5.5 Roche Recent Developments5.6 Celgene5.6.1 Celgene Profile5.6.2 Celgene Main Business5.6.3 Celgene Healthcare Nanotechnology Products, Services and Solutions5.6.4 Celgene Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.6.5 Celgene Recent Developments5.7 Sanofi5.7.1 Sanofi Profile5.7.2 Sanofi Main Business5.7.3 Sanofi Healthcare Nanotechnology Products, Services and Solutions5.7.4 Sanofi Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.7.5 Sanofi Recent Developments5.8 Merck & Co5.8.1 Merck & Co Profile5.8.2 Merck & Co Main Business5.8.3 Merck & Co Healthcare Nanotechnology Products, Services and Solutions5.8.4 Merck & Co Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.8.5 Merck & Co Recent Developments5.9 Biogen5.9.1 Biogen Profile5.9.2 Biogen Main Business5.9.3 Biogen Healthcare Nanotechnology Products, Services and Solutions5.9.4 Biogen Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.9.5 Biogen Recent Developments5.10 Stryker5.10.1 Stryker Profile5.10.2 Stryker Main Business5.10.3 Stryker Healthcare Nanotechnology Products, Services and Solutions5.10.4 Stryker Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.10.5 Stryker Recent Developments5.11 Gilead Sciences5.11.1 Gilead Sciences Profile5.11.2 Gilead Sciences Main Business5.11.3 Gilead Sciences Healthcare Nanotechnology Products, Services and Solutions5.11.4 Gilead Sciences Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.11.5 Gilead Sciences Recent Developments5.12 Pfizer5.12.1 Pfizer Profile5.12.2 Pfizer Main Business5.12.3 Pfizer Healthcare Nanotechnology Products, Services and Solutions5.12.4 Pfizer Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.12.5 Pfizer Recent Developments5.13 3M Company5.13.1 3M Company Profile5.13.2 3M Company Main Business5.13.3 3M Company Healthcare Nanotechnology Products, Services and Solutions5.13.4 3M Company Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.13.5 3M Company Recent Developments5.14 Johnson & Johnson5.14.1 Johnson & Johnson Profile5.14.2 Johnson & Johnson Main Business5.14.3 Johnson & Johnson Healthcare Nanotechnology Products, Services and Solutions5.14.4 Johnson & Johnson Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.14.5 Johnson & Johnson Recent Developments5.15 Smith & Nephew5.15.1 Smith & Nephew Profile5.15.2 Smith & Nephew Main Business5.15.3 Smith & Nephew Healthcare Nanotechnology Products, Services and Solutions5.15.4 Smith & Nephew Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.15.5 Smith & Nephew Recent Developments5.16 Leadiant Biosciences5.16.1 Leadiant Biosciences Profile5.16.2 Leadiant Biosciences Main Business5.16.3 Leadiant Biosciences Healthcare Nanotechnology Products, Services and Solutions5.16.4 Leadiant Biosciences Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.16.5 Leadiant Biosciences Recent Developments5.17 Kyowa Hakko Kirin5.17.1 Kyowa Hakko Kirin Profile5.17.2 Kyowa Hakko Kirin Main Business5.17.3 Kyowa Hakko Kirin Healthcare Nanotechnology Products, Services and Solutions5.17.4 Kyowa Hakko Kirin Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.17.5 Kyowa Hakko Kirin Recent Developments5.18 Shire5.18.1 Shire Profile5.18.2 Shire Main Business5.18.3 Shire Healthcare Nanotechnology Products, Services and Solutions5.18.4 Shire Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.18.5 Shire Recent Developments5.19 Ipsen5.19.1 Ipsen Profile5.19.2 Ipsen Main Business5.19.3 Ipsen Healthcare Nanotechnology Products, Services and Solutions5.19.4 Ipsen Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.19.5 Ipsen Recent Developments5.20 Endo International5.20.1 Endo International Profile5.20.2 Endo International Main Business5.20.3 Endo International Healthcare Nanotechnology Products, Services and Solutions5.20.4 Endo International Healthcare Nanotechnology Revenue (US$ Million) & (2015-2020)5.20.5 Endo International Recent Developments 6 North America6.1 North America Healthcare Nanotechnology Market Size by Country6.2 United States6.3 Canada 7 Europe7.1 Europe Healthcare Nanotechnology Market Size by Country7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific Healthcare Nanotechnology Market Size by Region8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America Healthcare Nanotechnology Market Size by Country9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa Healthcare Nanotechnology Market Size by Country10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 Healthcare Nanotechnology Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View post:
Healthcare Nanotechnology Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2026| Amgen, Teva Pharmaceuticals, Abbott - The...

2020-2025 Global and Regional Nanomedicine Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report -…

Posted on March 3, 2020 by Prof Baldwin

The global Nanomedicine market report by HNY Research offers users a detailed overview of the market and all the main factors affecting the market. The study on global Nanomedicine market, offers profound understandings about the Nanomedicine market covering all the essential aspects like revenue growth, supply chain, sales, key players and regions. There is a target set in market that every marketing strategy has to reach. This report on Nanomedicine focusses on different categories that define this market with a systematic approach that addresses the consumer base, researchers and market experts like the stakeholders. It also gives a clear perspective towards the competition and demand and supply chain.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4361506

Manufacturer Detail

By Market Players:Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences

By Application

By TypeQuantum dots, Nanoparticles, Nanoshells, Nanotubes, Nanodevices

The Nanomedicine market report also offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the global Nanomedicine market. This report on Nanomedicine has been very well drafted to benefit anyone studying it. There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. Every market research report follows a robust methodology to define its market value. By doing so, the Nanomedicine research study by HNY Research offers collection of information and analysis for each facet of the Nanomedicine market such as technology, regional markets, applications, and types.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2020-2025-global-and-regional-nanomedicine-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

This study can benefit investors and business owners in many ways. It studies the business models, strategies, growth, innovations and every information about manufacturers that can help make business predictions and fetch good results. Making right business decisions is an undeniable measure that needs to be taken for market growth. Every market has a set of manufacturers, vendors and consumers that define that market and their every move and achievements becomes a subject of studying for market researchers and other stakeholders. One of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Nanomedicine report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. Another important aspect of every market research report by HNY Research is the study of the key players or manufacturers driving the market forward. The process helps to analyze the opponent thoroughly.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4361506

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

See more here:
2020-2025 Global and Regional Nanomedicine Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report -...

Nanomedicine Market to Record Significant Revenue Growth during the Forecast Period 2020-2027 | Bio-Gate AG, Celgene Corporation and Johnson &…

Posted on April 25, 2020 by Prof Baldwin

(MENAFN - iCrowdNewsWire) Apr 18, 2020

The latest report on the Nanomedicine Market is now available at Reports and Data . It explains the contemporary and upcoming trends, along with the details associated with the regional landscape of the global Nanomedicine market.

The report further focuses on the details regarding the demand and supply analysis, contributions by the prominent industry players, and also the market share growth of the Nanomedicine market industry.

Comprehensive secondary research was carried out to collect the information on the Nanomedicine market and its parent and ancillary markets. Further, primary research was performed to validate the assumptions and findings obtained from secondary research. This report is an extensive analysis of the major insights related to this industry.

The report includes the latest coverage of the impact of COVID-19 on the Nanomedicine industry. The incidence has affected nearly every aspect of the business domain. This study evaluates the current scenario and predicts future outcomes of the pandemic on the global economy.

Have Queries? To request a sample or speak to an expert before you buy the report, click on the link below: https://www.reportsanddata.com/sample-enquiry-form/1048

In this report, we analyze the Nanomedicine market from two aspects: 1. Production In terms of production, the production, revenue, gross margin of its major manufacturers, and the unit price that they offer in different regions from 2020 to 2027 is analyzed.

2. Consumption In terms of consumption, the consumption volume, consumption value, sale price, and import and export status in different regions from 2020 to 2027 is analyzed.

Upstream and downstream consumer analysis is also carried out. It also focuses on the factors influencing the market, competitive landscape, data, trends, information, and exclusive vital statistics of the market.

Key players in the Nanomedicine market: Arrowhead Pharmaceuticals Inc. AMAG Pharmaceuticals, Bio-Gate AG, Celgene Corporation and Johnson & Johnson. Johnson & Johnson

Product Outlook (Revenue, USD Billion, 2018-2026) Therapeutics Regenerative Medicine In-vitro diagnostics In-vivo diagnostic Vaccines

Drug Delivery System Outlook (Revenue, USD Billion, 2018-2026) Nanobots Nanoghosts Nanoclusters Nanobubbles Exosomes Injectable Nanoparticle Generator Dendrimers Liposomes Carbon nanotube Graphene Others

Application Outlook (Revenue, USD Million, 2015-2026) Oncology Infectious diseases Cardiology Orthopedics Others

Grab Your Report at an Impressive Discount! Please Click Here @ https://www.reportsanddata.com/discount-enquiry-form/1048

The market study focuses on various key parameters that include: Market Segmentation Regional Segmentation In-Depth study of Market Determinants 360-Degree Economic Analysis Regulatory Analysis Company Profiling

Competitive Landscape: The competitive analysis of key market players is another remarkable feature of the Nanomedicine market industry report. The report offers company profiles of the major market players, product picture and its specifications, technology adopted by them, and future development plans. Moreover, the report sheds light on the strengths and weaknesses of the Nanomedicine companies to give readers a competitive advantage.

Market Segmentation: The segmentation is used to divide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising techniques, and sales efforts of the Nanomedicine market. Moreover, the report also compares the production value and growth rate of the Nanomedicine Market across different geographies.

This report studies the top producers and consumers, focused on product capacity, production value, consumption, market share, and growth opportunities in these.

The key regions covered are: North America (United States, Canada, and Mexico) Europe(Germany, France, UK, Russia, and Italy) Asia Pacific (China, Japan, Korea, India, and Southeast Asia) Latin America (Brazil, Argentina, Colombia) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Buy the Nanomedicine market report now by reaching out to us at: https://www.reportsanddata.com/checkout-form/1048

The research methodology used by the analysts to study the market includes inputs derived from the industry professionals across the value chain and various other secondary research methods.

Some of the Major Highlights of TOC are: Executive Summary Nanomedicine Market Insights Nanomedicine Market forecast by different Segments and Regions Manufacturing Cost Structure Analysis Development and Manufacturing Plants Analysis of the global Nanomedicine Market Key Figures of Major Manufacturers

Why purchase this report? The report would provide an in-depth analysis of the current and future market trends Analysis of global, regional, and country-level markets Key strategic initiatives taken by prominent players operating in the market Analysis based on historical data and current trends to estimate the future of the market Analysis of the impact of constantly changing global market scenarios Market Estimations

Access the Entire Report packed with TOC, Tables and Figures and Outline of Prominent Companies @ https://www.reportsanddata.com/report-detail/nanomedicine-market

Note: The historical years and forecast period can be customized on request. The scope of a published report can also be modified as per the requirements to include specific geography or country-based analysis part of customization.

John WatsonHead of Business DevelopmentReports And Data40 Wall St. 28th floor New York City, NY 10005 United StatesDirect Line: 1-212-710-1370E-mail: [email protected] Reports and Data | Web: http://www.reportsanddata.com

MENAFN1904202000703403ID1100047380

More:
Nanomedicine Market to Record Significant Revenue Growth during the Forecast Period 2020-2027 | Bio-Gate AG, Celgene Corporation and Johnson &...

Novartis signs collaboration deal with tiny Parvus for diabetes nanomedicine – FierceBiotech

Posted on April 22, 2017 by Prof Baldwin

Novartis, which has had a busy week for its CAR-T and NASH programs, today moved onto diabetes after penning a new pact with virtual Canadian biotech Parvus Therapeutics to use its leading tech.

Exact monetary terms werent given in the release, but Novartis gets exclusive, worldwide rights to use Parvus Navacims nanomedicine tech, specifically for diabetes patients with Type 1 (T1D), and will take on the clinical and sales work for this program.

On its side, privately owned Parvus will be primarily in charge of the ongoing preclinical work for the T1D program and filing an IND with Novartis.

Parvus has received an undisclosed upfront payment and will also gain a research funding boost to help out with its preclinical work. Biobucks have also been lined up, with Novartis in addition taking an equity investment in the biotech.

Navacims are made up of nanoparticles coated with disease-relevant peptide-major histocompatibility complexes. They are designed to change the behavior of disease-causing T lymphocytes.

Parvus says Navacims "are the first biopharmaceuticals to demonstrate in preclinical models the ability to restore immune tolerance in a disease-specific manner through in vivo formation and expansion of regulatory T-cells without causing general immune suppression, although they will need to go through many more years of clinical trials to assess efficacy and safety in humans.

But for Parvus, this is a major deal at an early stage from one of the biggest biomedical companies in the world, confirming its previously stated desire to team up with a Big Pharma.

This is a transformative collaboration for Parvus, said Janice LeCocq, CEO of Parvus. We are excited by this strong endorsement of the science behind our Navacim platform, as well as the opportunity to collaborate closely with a globally recognized leader in the field of immunology and autoimmune disease.

This will augment our resources across the Navacim platform and accelerate the development of our T1D program."

The company will also continue work on using Navacims against autoimmune diseases, notably where there is high unmet need for disease-modifying drugs that do not cause systemic immunosuppression.

More:
Novartis signs collaboration deal with tiny Parvus for diabetes nanomedicine - FierceBiotech

Growth in the Global Nanomedicine Market 2017-2021 trends, forecasts, analysis – satPRnews (press release)

Posted on August 25, 2017 by Prof Baldwin

Global Nanomedicine Market 2017-2021

This Nanomedicine market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Download sample pages of this report:http://tinyurl.com/y7bs9wea

Data integration and capabilities are analyzed to support the findings and study the predicted geographical segmentations. Various key variables and regression models were considered to calculate the trajectory of Nanomedicine market. Detailed analysis is explained and given importance to with best working models.

Geographically, the segmentation is done into several key regions like North America, Middle East & Africa, Asia Pacific, Europe and Latin America. The production, consumption, revenue, shares in mill UDS, growth rate of Nanomedicine market during the forecast period of 2017 to 2021 is well explained.

The ongoing market trends of Nanomedicine market and the key factors impacting the growth prospects are elucidated. With increase in the trend, the factors affecting the trend are mentioned with perfect reasons. Top manufactures, price, revenue, market share are explained to give a depth of idea on the competitive side.

Each and every segment type and their sub types are well elaborated to give a better idea about this market during the forecast period of 2017 to 2021 respectively.

Download sample pages of this report:http://tinyurl.com/y7bs9wea

About Us:Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Contact:

Mr. Mannansales@kminsights.com+1 (888) 278-7681

Read this article:
Growth in the Global Nanomedicine Market 2017-2021 trends, forecasts, analysis - satPRnews (press release)

The EPR Effect and its Relevance to Nanomedicine and Cancer Therapeutics – Video

Posted on March 5, 2015 by Prof Baldwin

The EPR Effect and its Relevance to Nanomedicine and Cancer Therapeutics
Speaker: Prof. Dr. Alberto A. Gabizon, Hebrew University - School of Medicine - Shaare Zedek MC Oncology Institute, Jerusalem (IL) CLINAM 7/ 2014, 7th Confer...

By: TAUVOD

View original post here:
The EPR Effect and its Relevance to Nanomedicine and Cancer Therapeutics - Video

Select Page ::